 LEIDEN, Netherlands CAMBRIDGE, Mass., March 30, 2021 GLOBE NEWSWIRE -- ProQR Therapeutics N.V. Nasdaq: PRQR, a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases IRDs, today announced that it intends to offer and sell its ordinary shares in an underwritten public offering. All of the shares are being offered by ProQR. In addition, ProQR expects to grant the underwriters a 30-day option to purchase up to an additional 15 of the offering amount in ordinary shares at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market conditions and other closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual terms of the offering. 